Here you will find a complete list of all ongoing trials for hepatitis delta.
And here you will find a list of all completed clinical trials evaluating therapies for hepatitis delta.
FDA Grants Fast Track Designation to Eiger Bio's Lonafarnib for Hepatitis Delta Virus (HDV) Infection
PALO ALTO, Calif., April 20, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, lonafarnib, in combination with ritonavir for treatment of hepatitis delta virus (HDV) infection. Lonafarnib is currently in Phase 2 clinical trials for this indication.
Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta
Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients with chronic hepatitis B (HBV) and delta (HDV). The results suggest that Myrcludex B may become an option for treating hepatitis delta. With details to be presented at the AASLD meeting in Boston in November 2014, the trials also indicate positive results for the treatment of HBV infection.